FDA Arthritis Drugs Advisory Committee
Will discuss "NDA Day" procedures and objectives and the role of the committee in the review of Rx Jan. 27-28 meeting. In June, the arthritis committee participated in the review of Syntex/Procter & Gamble's naproxen sodium OTC switch application and recommended against approval. A review of Greenwich Pharmaceuticals Therafectin, which was rejected by FDA in November, is set for Jan. 27. The meeting takes place in conference rooms D&E of FDA's Parklawn building beginning at 8:30 a.m. each day
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth